Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen executive Compensation (DEF 14A) — CEO Pay Ratio (x:1) (×)
DEF 14A Proxy Statement — CEO Pay Ratio Disclosure
Latest, FY2025
160.00
Period ended Dec 31, 2025
Change on a year earlier
+4.6%
153.00 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Executive Compensation (DEF 14A) — CEO Pay Ratio (x:1) (×) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 160.00 | +4.6% | Proxy Statement (DEF 14A) (d13946ddef14a.htm, filed 2026-04-07) ↗ |
| FY2024 | Dec 31, 2024 | 153.00 | +12.5% | Proxy Statement (DEF 14A) (amgn-20250408.htm, filed 2025-04-09) ↗ |
| FY2023 | Dec 31, 2023 | 136.00 | -14.5% | Proxy Statement (DEF 14A) (d445034ddef14a.htm, filed 2024-04-17) ↗ |
| FY2022 | Dec 31, 2022 | 159.00 | -4.2% | Proxy Statement (DEF 14A) (d371686ddef14a.htm, filed 2023-04-06) ↗ |
| FY2021 | Dec 31, 2021 | 166.00 | +9.2% | Proxy Statement (DEF 14A) (d234450ddef14a.htm, filed 2022-04-05) ↗ |
| FY2020 | Dec 31, 2020 | 152.00 | +1.3% | Proxy Statement (DEF 14A) (d107745ddef14a.htm, filed 2021-04-06) ↗ |
| FY2019 | Dec 31, 2019 | 150.00 | – | Proxy Statement (DEF 14A) (d846287ddef14a.htm, filed 2020-04-07) ↗ |
Breakdown
What makes up executive compensation (def 14a) — ceo pay ratio (x:1)
Cite this data
StockData. (2026). Amgen Executive Compensation (DEF 14A) — CEO Pay Ratio (x:1) (×), annual FY2019–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/proxy_pay_ratio
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.